These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8054461)

  • 21. Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation.
    Uchikawa Y; Ikegami T; Masuda Y; Ohno Y; Mita A; Urata K; Nakazawa Y; Terada M; Miyagawa S
    Transplant Proc; 2009 Nov; 41(9):3784-90. PubMed ID: 19917388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation management during cross-clamping and bypass.
    Lander H; Zammert M; FitzGerald D
    Best Pract Res Clin Anaesthesiol; 2016 Sep; 30(3):359-70. PubMed ID: 27650345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
    Thelin S; Bagge L; Hultman J; Borowiec J; Nilsson L; Thorelius J
    Eur J Cardiothorac Surg; 1991; 5(9):486-91. PubMed ID: 1931093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
    Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
    Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
    Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study.
    Shi XB; Bai Y; Li J; Xiao J; Wang JQ; Zheng H
    Chin Med J (Engl); 2013; 126(18):3553-6. PubMed ID: 24034107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time.
    Jessen LR; Wiinberg B; Jensen AL; Kjelgaard-Hansen M; Jensen KH; Pedersen LB; Kristensen AT
    Vet Clin Pathol; 2008 Dec; 37(4):363-72. PubMed ID: 19055570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Schumacher WA; Heran CL; Steinbacher TE
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
    Jeffrey RF; Khan AA; Douglas JT; Will EJ; Davison AM
    Artif Organs; 1993 Aug; 17(8):717-20. PubMed ID: 8215953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.